Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2740 - Clinical outcomes and testosterone levels following continuous androgen deprivation (CAD) in patients with relapsing or locally advanced prostate cancer (PC): A post hoc analysis of the ICELAND study


09 Oct 2016


Poster display


Bertrand Tombal


Annals of Oncology (2016) 27 (6): 243-265. 10.1093/annonc/mdw372


B.F. Tombal1, E. Cornel2, V. Matveev3, T.L. Tammela4, J. Schraml5, W. Warnack6, R. Persad7, A. Stari8, F.G. Veiga9, C. Schulman10

Author affiliations

  • 1 Urology, Cliniques universitaires Saint Luc, 1200 - Brussels/BE
  • 2 Urology, Ziekenhuis Groep Twente, Hengelo/NL
  • 3 Urology, N. N. Blokhin Russian Cancer Research Center, Moscow/RU
  • 4 Urology, Tampere University hospital (Tays), Tampere/FI
  • 5 Urology And Robotic Surgery, Masaryk Hospital and University of J.E. Purkyně, Usti nad Labem/CZ
  • 6 Urology, Warnack Private Practice, Hagenow/DE
  • 7 Urology/surgery, University of Bristol and Bristol Urological Institute, Bristol/GB
  • 8 Medical Affairs, Astellas Pharma Inc., London/GB
  • 9 Urology, Hospital Universitario de Salamanca, Salamanca/ES
  • 10 Urology, Clinic Edith Cavell - University of Brussels, B-1180 - Brussels/BE


Abstract 2740


ICELAND is a large multicentre EU study demonstrating similar efficacy, tolerability and QOL with CAD and intermittent androgen deprivation (IAD) with leuprorelin (Eligard®) in non-metastatic PC. This post hoc analysis investigated if patients (pts) achieving serum testosterone (T) levels of ≤20 ng/dL within the 1st year of CAD have improved cause-specific survival (CSS) and time to PSA [castrate-resistant prostate cancer (CRPC)] progression.


Pts with locally advanced or relapsing non-metastatic PC following radical prostatectomy or radiotherapy were enrolled in this prospective, phase IIIb, open-label, randomised study (NCT00378690). After a 6-month induction with leuprorelin (Eligard®) 3-month depot 22.5 mg (plus bicalutamide 50 mg/day for 1 month), pts with PSA levels ≤1 ng/mL were randomised 1:1 to CAD (n = 361) or IAD (n = 340) with leuprorelin (Eligard®) for 36 months. Pts receiving CAD therapy were stratified by min, median and max T levels achieved during the 1st year of therapy into ≤20, 20-50 and >50 ng/dL T subgroups. CSS and time to PSA (CRPC) progression were analysed by Kaplan-Meier analyses and Cox proportional hazards regression model.


A total of 90.1%, 83.5% and 74.5% of pts receiving CAD achieved minimum, median and maximum serum T levels of ≤20 ng/dL, respectively. CSS rates and time to PSA (CRPC) progression did not differ significantly between T subgroups (table).

Testosterone level (ng/dL) N Time to cause-specific survival Time to PSA (CRPC) progression
% (95% CI) HR (95% CI) p valuea % (95% CI) HR (95% CI) p valuea
≤20 311 90.5 (87.2–93.8) 1 99.0 (97.9–100.0) 1
>20 − ≤50 33 86.7 (74.5–100.0) 0.89 (0.4–1.8) 0.849 92.4 (83.3–100.0) 5.06 (1.3–16.1) 0.062
>50 1 100.0 (100.0–100.0) NE 100.0 (100.0–100.0) NE
≤20 288 90.2 (86.8–93.7) 1 98.9 (97.8–100.0) 1
>20 − ≤50 54 89.1 (80.6–98.9) 0.84 (0.4–1.6) 0.598 95.4 (89.8–100.0) 3.92 (1.2–12.3) 0.083
>50 3 83.3 (56.7–100.0) 2.74 (0.2–12.7) 100.0 (100.0–100.0) NE
≤20 257 90.6 (87.0–94.2) 1 99.2 (98.1–100.0) 1
>20 − ≤50 78 87.8 (80.3–95.5) 1.13 (0.6–1.9) 0.196 96.8 (92.9–100.0) 2.79 (0.8–9.3) 0.165
>50 10 83.3 (59.5–100.0) 3.59 (0.9–10.0) 95.0 (85.7–100.0) 4.57 (0.2–26.8)

CI, confidence interval; HR, hazard ratio; CRPC, castrate-resistant prostate cancer; NE, not estimable; PSA, prostate-specific antigen. aLikelihood ratio test.


In pts receiving CAD, CSS and time to PSA (CRPC) progression did not differ according to T levels in the 1st year of therapy. This finding may have been due, at least in part, to the effectiveness of leuprorelin (Eligard®) in lowering T, as maximum T levels ≤20 ng/dL were achieved in 75% of pts over the 1st year of CAD.

Legal entity responsible for the study

Astellas Pharma, Inc. and Medivation, Inc.


Astellas Pharma, Inc. and Medivation, Inc.


B. Tombal: Advisory board member: Astellas, Bayer, Medivation, Ferring, Amgen, Sanofi. Aventis. Corporate-sponsored research: Astellas, Bayer, Medivation, Ferring, Amgen, Sanofi Aventis.

T.L. Tammela: Advisory board member: Astellas, Orion Pharma, Bayer. Corporate-sponsored research: Astellas, Orion Pharma, Medivation, Jansen-Cilag, Bayer, Ferring, Camurus Ab, Lidds Ab.

All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings